Friday, November 13, 2026

Corporate M&A and Restructuring

2 articles

Corporate Restructuring Surge Fuels Double-Digit Earnings Growth and $500M Buyback Programs

Corporate Restructuring Surge Fuels Double-Digit Earnings Growth and $500M Buyback Programs

CFOs across multiple sectors project 9-11% revenue growth and EBITDA margins exceeding 23.5% for 2026 as major restructuring deals reshape capital structures. Keurig Dr Pepper's JDE Peet's acquisition and Siemens' two-company split anchor a wave of strategic realignments. Companies are authorizing aggressive capital returns including $500 million stock repurchases amid improved cash flow generation.

ViaNews Editorial Team (Finance)•
Corporate Finance Chiefs Navigate $15B+ M&A Wave as Restructuring Accelerates in 2026

Corporate Finance Chiefs Navigate $15B+ M&A Wave as Restructuring Accelerates in 2026

CFO transitions are accelerating across companies pursuing strategic separations and cross-border acquisitions, with Siemens leading restructuring efforts while Gartner and EXL target double-digit earnings growth. Constellation delivered its fourth consecutive year of above-guidance performance, while Keurig Dr Pepper and JDE Peet's explore merger opportunities. The wave signals leadership changes accompanying transformation initiatives valued at over $15 billion.

ViaNews Editorial Team (Finance)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com